Submissions for variant NM_000256.3(MYBPC3):c.1072G>A (p.Asp358Asn)

gnomAD frequency: 0.00003  dbSNP: rs746267533

Total submissions: 4

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Invitae	RCV000471355	SCV000546463	uncertain significance	Hypertrophic cardiomyopathy	2022-06-02	criteria provided, single submitter	clinical testing	This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 358 of the MYBPC3 protein (p.Asp358Asn). This variant is present in population databases (rs746267533, gnomAD 0.02%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 25351510, 27532257). ClinVar contains an entry for this variant (Variation ID: 407328). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics	RCV000617458	SCV000736639	uncertain significance	Cardiovascular phenotype	2021-08-06	criteria provided, single submitter	clinical testing	The p.D358N variant (also known as c.1072G>A), located in coding exon 12 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 1072. The aspartic acid at codon 358 is replaced by asparagine, an amino acid with highly similar properties. This variant has been reported in hypertrophic cardiomyopathy cohorts; however, clinical details were limited (Lopes LR et al. Heart. 2015;101:294-301; Walsh R et al. Genet Med. 2017 02;19(2):192-203). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Color Diagnostics, LLC DBA Color Health	RCV001181626	SCV001346809	uncertain significance	Cardiomyopathy	2023-02-02	criteria provided, single submitter	clinical testing	This missense variant replaces aspartic acid with asparagine at codon 358 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 25351510, 27532257, 33495597). This variant has been identified in 10/280354 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
PreventionGenetics, part of Exact Sciences	RCV003401468	SCV004103479	uncertain significance	MYBPC3-related condition	2023-05-26	criteria provided, single submitter	clinical testing	The MYBPC3 c.1072G>A variant is predicted to result in the amino acid substitution p.Asp358Asn. This variant has been reported in an individual with hypertrophic cardiomyopathy as part of a large cohort study (Table S1A, Walsh et al 2017. PubMed ID: 27532257). This variant is reported in 0.016% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/11-47367776-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.